Müller G A, Müller C, Bockhorn H, Lenhard V, Dreikorn K, Fetta R F, Wilms H, Fassbinder W, Gumbel B, Albert F W, Ewald R W, Goldmann S, Sprenger-Klasen I, Franz H E, Wernet P
Klin Wochenschr. 1983 Jan 3;61(1):17-23. doi: 10.1007/BF01484435.
The influence of prospective HLA-DR matching on the graft survival rate was investigated in a multicenter analysis of 85 transplants. Simultaneously in a retrospective analysis of graft outcome the importance of matching for MT-antigens MT1, MT2 and MT3 as a newly defined B-cell alloantigen system was evaluated. HLA-DR antigens and MT-specificities were determined on B-cells enriched by nylon-wool filtration using locally well characterised HLA-DR antisera and the antiserum set of the 8th International Histocompatibility Workshop ("disease set") which allowed the definition of the HLA-DR specificities HLA-DR 1-9 and of the MT-antigens MT1-3. HLA-DR matching showed a significantly improved graft outcome only in HLA-DR identical donor-recipient combinations. In 11 of 60 patients with one HLA-DR compatibility additional matching for two MT-antigens, however, improved the two year graft survival rate from 60% to 91%. Altogether 17 patients were matched for two MT-specificities with their kidney donor and showed a superior prognosis of 94% at two years compared to 53% or 17% of recipients with one or zero MT compatibility. Graft outcome in this patient group was also superior to that of HLA-DR identical or HLA-AB identical grafts. These data suggested that the MT-system rather than the HLA-DR antigens may be of critical importance in cadaver kidney transplantation. In addition a favorable influence of pretransplant blood transfusions on less HLA-DR matched grafts was confirmed.
在一项对85例移植手术的多中心分析中，研究了前瞻性HLA - DR配型对移植物存活率的影响。同时，在一项关于移植物结果的回顾性分析中，评估了作为新定义的B细胞同种异体抗原系统的MT抗原MT1、MT2和MT3配型的重要性。使用本地充分表征的HLA - DR抗血清和第8届国际组织相容性研讨会的抗血清组（“疾病组”），对通过尼龙毛过滤富集的B细胞进行HLA - DR抗原和MT特异性检测，该抗血清组可定义HLA - DR特异性HLA - DR 1 - 9和MT抗原MT1 - 3。仅在HLA - DR完全相同的供受者组合中，HLA - DR配型显示移植物结果有显著改善。然而，在60例有一个HLA - DR相容性的患者中，有11例额外匹配了两种MT抗原，这使得两年移植物存活率从60%提高到了91%。共有17例患者与其肾脏供者匹配了两种MT特异性，与有一个或零个MT相容性的受者相比，两年时预后良好率为94%，而后者分别为53%或17%。该患者组的移植物结果也优于HLA - DR相同或HLA - AB相同的移植物。这些数据表明，在尸体肾移植中，MT系统而非HLA - DR抗原可能至关重要。此外，还证实了移植前输血对HLA - DR匹配度较低的移植物有有利影响。
